KalVista Pharmaceuticals Inc Stock News

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of

Geode Capital Management LLC increased its position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 16.9% during the first quarter, according to its most recent Form 13F filing with the Sec

The

Celebrations may be in order for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shareholders, with the analysts...

The

In a report released today, Serge Belanger from Needham downgraded Zynerba Pharmaceuticals (ZYNE – Research Report) to Hold. The company’s

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verrica Pharmaceuticals

In a report released today, Serge Belanger from Needham assigned a Buy rating to Zogenix (ZGNX – Research Report), with

In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),

In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI – Research Report),